Pretargeted antibody-guided radioimmunotherapy in a child affected by resistant anaplastic large cell lymphoma.
Anaplastic large cell lymphoma (ALCL) is characterized by preferential paracortical and intrasinusoidal lymph node involvement by large anaplastic tumor cells expressing the CD30 antigen. Up to 80% of pediatric patients with ALCL can be cured with multi-agent chemotherapeutic regimens. Patients resistant to chemotherapy or suffering from early relapse have a poor prognosis and a poor chance of survival. In these cases, the highly aggressive clinical course of ALCL, associated with systemic symptoms and extranodal involvement, has been treated with different approaches in various cooperative trials, including conventional chemotherapy and human stem cell transplantation (HSCT). However, the optimal treatment has not yet been defined, in particular in cases of relapse. More recently, radioimmunotherapy has been studied with encouraging results in cancer patients, including non-Hodgkin's lymphoma. Here we describe the case of a pediatric ALCL, relapsing after HSCT, treated with pretargeted antibody-guided radioimmunotherapy, obtaining a complete remission, with excellent quality of life over the past 10 months.
Palumbo
Giuseppe
G
Department of Public Health and Cell Biology, Pediatrics, University of Rome Tor Vergata c/o Ospedale S. Eugenio, Rome, Italy. palumbogiu@tiscali.it
Grana
Chiara M
CM
Cocca
Francesca
F
De Santis
Rita
R
Del Principe
Domenico
D
Baio
Silvia M
SM
Mei
Riccardo
R
Paganelli
Giovanni
G
D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D002648:Child; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D017728:Lymphoma, Large-Cell, Anaplastic / Q000000981:diagnostic imaging*; D016499:Radioimmunotherapy / Q000379:methods*; D011877:Radionuclide Imaging; D016879:Salvage Therapy / Q000379:methods
D000912:Antibodies, Neoplasm